Term ends Dec 2, 2040 · Medium confidence
20-year base term ends Dec 2, 2040
Why Medium: A parent in the chain could not be resolved.
Held by Iovance Biotherapeutics, Inc.
Filed Mar 1, 2022 as application 17/684,106 · Granted Feb 7, 2023
Base term, 20 years from filing
Today
2020
2040
Clock starts
Dec 2, 2020
Dec 2, 2020
Term ends
Dec 2, 2040
Dec 2, 2040
Granted
Feb 7, 2023
Feb 7, 2023
base term
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
20
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 2, 2020, when application 17/110,104, the earliest non-provisional in its chain, was filed (this one was filed Mar 1, 2022); a parent in its chain could not be resolved (the next row) | Dec 2, 2040 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 2, 2040 | Medium confidence |
This family
| Application 17/110,104 | Abandoned not computed | not computed |
| US 11,292,822 | In force Dec 2040 | Dec 2040 |
| US 11,572,397 | this patent Dec 2040 | Dec 2040 |
| US 11,613,563 | In force Dec 2040 | Dec 2040 |
| US 11,608,368 | In force Dec 2040 | Dec 2040 |
| US 12,268,903 | In force Aug 2042 | Aug 2042 |
| US 11,629,178 | In force Dec 2040 | Dec 2040 |
| US 11,618,775 | In force Dec 2040 | Dec 2040 |
8 of 20 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 5, 2022 Reel 60397, frame 70 | Mumm, John | Deka Biosciences, Inc. | Assignment of Assignor's Interest |
| Aug 28, 2026 Reel 75830, frame 409 | Deka Biosciences, Inc. | Deka (Assignment for the Benefit of Creditors), LLC | Assignment of Assignor's Interest |
| Aug 28, 2026 Reel 75830, frame 464 | Deka (Assignment for the Benefit of Creditors), LLC | Iovance Biotherapeutics, Inc. | Assignment of Assignor's Interest |
| Oct 2, 2026 Reel 76613, frame 861 | Iovance Biotherapeutics, Inc. | Iovance Biotherapeutics, Inc. | Change of Address |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2040
Term ends Dec 2, 2040.
Citations
13
later US patents cite this one
That is top 5% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.